Basilea-Astellas' antifungal treatment gets orphan status from FDA

05/29/2013 | Pharmaceutical Business Review Online

The FDA granted orphan-drug designation to Basilea Pharmaceutica and Astellas Pharma's experimental antifungal isavuconazole as a treatment for invasive aspergillosis. The intravenous and oral-broad spectrum drug is in late-stage studies for severe invasive fungal infections.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park